ADDEX THERAPEUTICS LTD

ADXNNASDAQ

🏆 #5210 by market capUS Equity

$3.32▼ $0.15 (−4.46%)

Live

🔔

Track ADXN

Get earnings, price moves & breaking news on Telegram

Track

24h▼ 4.5%

7d▼ 4.5%

14d▼ 9.7%

30d▼ 18.6%

ytd▼ 58.5%

1y▼ 67.9%

🏦Market Cap

$4M

Small Cap

📈Revenue Growth (YoY)

-92.6%

Declining

📊Gross Margin

84.3%

High

💵FCF Margin

-2609.7%

Thin

⚖️P/S Ratio

41.7x

Expensive

Otter Score

Fair

Trading Snapshot

Day Range: $3.27 – $3.35
52-Week Range: $3.10 – $11.97
Volume: $4.02B
Avg Volume: $4.49B
Shares Outstanding: 1.2M
Next Earnings: Nov 26, 2026

Fundamentals Snapshot

Annual Revenue: $107,842
Last Q Revenue: $29,156
P/E Ratio: -0.4
P/S Ratio: 41.7x
EPS (TTM): $-4.88
Dividend Yield: 0.00%

Why Investors Own ADXN

✓High-growth profile — revenue up +13.4% YoY with expanding US Equity exposure.
✓Healthy economics — 56% gross margin and 5% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

ADDEX THERAPEUTICS LTD

ADXN

Financial Trends

Revenue (TTM)

$107,842▲ +19.0% YoY

Gross Margin (TTM)

55.9%▲ +3.7% YoY

Operating Income (TTM)

$16,068▲ +19.0% YoY

Free Cash Flow (TTM)

$5,608▲ +19.0% YoY

StockOtter · stockotter.space

About ADDEX THERAPEUTICS LTD

Addex Therapeutics Ltd, a biopharmaceutical firm in a developmental phase, operates out of Switzerland, focusing on the discovery, advancement, and commercialization of small-molecule drugs targeting central nervous system (CNS) disorders. Their core strategy involves identifying oral small-molecule allosteric modulators for G-protein coupled receptors. The company's key programs include Dipraglurant, an investigational treatment for Parkinson's disease levodopa-induced dyskinesia and dystonia; ADX71149, which is being developed for epilepsy and other unspecified CNS conditions; and GABAB PAM, a compound aimed at treating addiction. Addex Therapeutics has established licensing and collaboration agreements with significant partners, including Janssen Pharmaceuticals Inc., Indivior PLC, and The Charcot–Marie–Tooth Association. Founded in 2002 and based in Geneva, Switzerland, the company was initially known as Addex Pharmaceuticals Ltd before officially changing its name to Addex Therapeutics Ltd in March 2012.

🦦